| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9f0bd8dbdc62695ef8fadcfaf8960cb1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_812ff8a0d8aae226ef8f7678a68a9497 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-33 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02 |
| filingDate |
2001-11-29^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-07-18^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45e3c53b81e5b242d5650abcdce1ccf4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08888b2624a165691d8b49c2f0e093e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e835a1b804f040e35ef75cc710bd33de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d145a75a7655e435918b21479a0e1ee4 |
| publicationDate |
2012-07-18^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1435999-B1 |
| titleOfInvention |
Combination of two bioactive regions of pro-opiomelanocortin hormone |
| abstract |
Computational analysis was used to define repetitive and bioactive regions of the pro-opiomelanocortin SYSMEHFRWGKPV and YGGFM. Cytoprotection model of the ethanol induced gastric lesion was used to prove the additive cytoprotective effects of the combination of sequences SYSMEHFRWGKPV and YGGFM, when compared to the individual peptid sequences. The combination of two sequences SYSMEHFRWGKPV and YGGFM is denoted KOMET and patented. The purpose of the administration of KOMET is to obtain better and stronger pharmacologic effects on the systemic and local modulation of the inflammation and wound healing. Additional structural formulas which represent different combinations of both sequences were also defined as: KOMET-1 with sequence YGGFMSYSMEHFRWGKPVYGGFM, KOMET-2 with sequence YGGFMSYSMEHFRWGKPV and KOMET-3 with sequence SYSMEHFRWGKPVYGGFM. |
| priorityDate |
2001-10-18^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |